Maraviroc to Augment Rehabilitation Outcomes After Stroke
Public ClinicalTrials.gov record NCT03172026. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT03172026
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- University of California, Los Angeles
- Other
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Interventions
- Maraviroc 300 mg Drug
- Rehabilitation therapy Behavioral
- Placebo 300 mg Drug
Drug · Behavioral
Eligibility (public fields only)
- Age range
- 30 Years to 86 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2019
- Primary completion
- Sep 30, 2020
- Completion
- Sep 30, 2020
- Last update posted
- Aug 2, 2021
2019 – 2020
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Rehabilitation Institute | Los Angeles | California | 90067 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Burke Neurological Research Institute | White Plains | New York | 10605 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03172026, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03172026 live on ClinicalTrials.gov.